HomeAI · summaries
Storia in 3 fonti
FDA approves Nuvalent's cancer drug, a week after GSK closed $10.6B buyout
The agency greenlit Jideytro for patients who have been previously treated with a ROS1 kinase inhibitor for ROS1-positive non-small cell lung cancer.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
benzinga.com
FDA Greenlights GSK’s First Lung Cancer Drug Ahead of Schedule - GSK (NYSE:GSK)
GSK wins early FDA approval for Jideytro, a targeted treatment for adults with advanced ROS1-positive non-small cell lung cancer.
- ·
endpoints.news
FDA approves Nuvalent's cancer drug, a week after GSK closed $10.6B buyout
The agency greenlit Jideytro for patients who have been previously treated with a ROS1 kinase inhibitor for ROS1-positive non-small cell lung cancer.
